This biotech innovator develops peptide-based therapies for blood and immune disorders, advancing a pipeline of clinical-stage candidates.
Hedge fund BVF reported a full exit from Protagonist Therapeutics (PTGX 0.41%) in its February 17, 2026, SEC filing, selling 2,560,916 shares worth an estimated $170.12 million.
What happened
According to its SEC filing dated February 17, 2026, BVF fully liquidated its stake in Protagonist Therapeutics (PTGX 0.41%), selling 2,560,916 shares. The quarter-end position value decreased by $170.12 million.
What else to knowBVF sold out of Protagonist Therapeutics.Top holdings after the filing:NASDAQ:KYMR: $428.17 million (14.4% of AUM)NASDAQ:RVMD: $267.37 million (9.0% of AUM)NASDAQ:MLTX: $260.32 million (8.8% of AUM)NASDAQ:GPCR: $241.97 million (8.1% of AUM)NASDAQ:OLMA: $132.40 million (4.5% of AUM)As of February 17, 2026, shares of Protagonist Therapeutics were priced at $82.46, up 120% over the past year and significantly outperforming the S&P 500’s roughly 13% gain in the same period.Company overviewMetricValueMarket Capitalization$5.16 billionRevenue (TTM)$209.22 millionNet Income (TTM)$45.91 millionPrice (as of market close 2/17/26)$82.46Company snapshotProtagonist Therapeutics develops peptide-based therapeutics targeting hematology, blood disorders, and inflammatory diseases.The firm generates revenue through proprietary drug development and strategic licensing and collaboration agreements.Headquartered in Newark, California, it focuses on advancing mid-stage clinical assets in hematology and immunology.
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company leveraging peptide technology to address unmet needs in hematology and immunology. The company’s strategic partnerships and robust pipeline position it as a key innovator within the biotechnology sector. Its focus on advancing mid-stage clinical assets supports long-term growth potential and competitive differentiation.
What this transaction means for investors
Biotech exits are rarely random. Instead, they tend to cluster around inflection points, and Protagonist has been hitting them. In January, Takeda and Protagonist announced submission of a New Drug Application for rusfertide in polycythemia vera, backed by 52-week Phase 3 VERIFY data that met the primary and all four key secondary endpoints. The drug also carries Breakthrough Therapy and Fast Track designations. In short, this is no longer a science project. It is a regulatory story.
When a clinical-stage biotech rallies 120% in a year and files an NDA, the risk profile changes. Execution, labeling, commercial structure and royalty economics start to matter more than trial design. Of course, the submission happened after quarter’s end, but the firm had been teasing it for months.
Within a portfolio dominated by concentrated biotech bets like Kymera, Revolution Medicines and MoonLake, trimming or exiting after a major milestone is consistent with disciplined capital rotation. This fund often leans into earlier-stage upside and redeploys when binary risk compresses into regulatory review.
For long-term investors, the key question is not why someone sold. It is what happens next. If rusfertide wins approval and reshapes polycythemia vera treatment, fundamentals will ultimately drive value. But post-NDA, expectations might reset.
Comments (0)